Published Online
on September 8, 2008

A more recent version of this article appeared on October 1, 2008

This Article Full Text (PDF) All Versions of this Article: 52/4/601    most recent HYPERTENSIONAHA.105.063651v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pacher, P. Articles by Kunos, G. Search for Related Content PubMed PubMed Citation Articles by Pacher, P. Articles by Kunos, G. Related Collections Other heart failure Obesity Cardiovascular Pharmacology Cerebrovascular disease/stroke Pathophysiology Myocardial cardiomyopathy disease Glucose intolerance

Submitted on April 3, 2008
Revised on April 30, 2008

Modulation of the Endocannabinoid System in Cardiovascular Disease. Therapeutic Potential and Limitations

Pál Pacher^*; Partha Mukhopadhyay; Rajesh Mohanraj; Grzegorz Godlewski; Sándor Bátkai; and George Kunos

From the Sections on Oxidative Stress Tissue Injury (P.P., P.M., R.M.), and Neuroendocrinology (G.G., S.B., G.K.), Laboratory of Physiological Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Md.

^* To whom correspondence should be addressed. E-mail: pacher{at}mail.nih.gov.

This article has been cited by other articles:

				P. Pacher Cannabinoid CB1 Receptor Antagonists for Atherosclerosis and Cardiometabolic Disorders: New Hopes, Old Concerns? Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 7 - 9. [Full Text] [PDF]